Nikolas Tripodis - Santen Pharmaceutical Chief Officer

All Insiders . USA . 
Stock . Santen Pharmaceutical Co . Stakeholders . Insider . Nikolas Tripodis
SNPHF Stock  USD 10.15  0.09  0.88%   

Insider

Nikolas Tripodis is Chief Officer of Santen Pharmaceutical Co
Phone81 6 7664 8621
Webhttps://www.santen.com

Santen Pharmaceutical Management Efficiency

Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Santen Pharmaceutical Co has accumulated 32.93 B in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Santen Pharmaceutical has a current ratio of 2.43, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Santen Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Santen Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santen Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santen to invest in growth at high rates of return. When we think about Santen Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Aradhana MDAstraZeneca PLC ADR
50
Timothy PowerBristol Myers Squibb
N/A
Tim PowerBristol Myers Squibb
N/A
Patrice BulaNovartis AG ADR
65
MBA DVMAstraZeneca PLC ADR
65
Dante BeccariaSanofi ADR
N/A
Paul HudsonSanofi ADR
57
Chris SheldonAstraZeneca PLC ADR
N/A
Michelle WeeseBristol Myers Squibb
50
Michael QuigleyGilead Sciences
N/A
Diane WilfongGilead Sciences
62
Paula PriceBristol Myers Squibb
59
Robert KowalskiNovartis AG ADR
53
Samir MDNovartis AG ADR
62
Derica RiceBristol Myers Squibb
56
Nadim AhmedBristol Myers Squibb
51
Greg MeyersBristol Myers Squibb
51
Karen HaleNovartis AG ADR
56
Charlotte WieserNovartis AG ADR
N/A
Robert PharmDNovartis AG ADR
56
Paul PenepentNovartis AG ADR
N/A
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people. Santen Pharmaceutical Co [SNPHF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity-0.0264
Return On Asset-0.001

Santen Pharmaceutical Leadership Team

Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Satoshi Suzuki, Executive Officer, Chief Director of Planning
Nobuko Kato, Chief Officer
Mika Masunari, G Officer
Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer
Nikolas Tripodis, Chief Officer
Kaori Itagaki, Gen Group
Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit
Shinichi Teramachi, Head Officer
Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR
Ippei Kurihara, Japan Department
Minori Hara, Chief Officer

Santen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.0264
Return On Asset-0.001
Profit Margin(0.03) %
Operating Margin(0) %
Current Valuation2.6 B
Shares Outstanding388.22 M
Shares Owned By Insiders3.21 %
Shares Owned By Institutions53.50 %
Price To Earning14.54 X
Price To Book1.39 X

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Santen Pink Sheet

Santen Pharmaceutical financial ratios help investors to determine whether Santen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santen with respect to the benefits of owning Santen Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY